VAUGHAN, ON , Sept. 21, 2022 /PRNewswire/ — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced that data from the National Eye Institute’s (NEI) 10-Year Follow-on Research Results of the Age-Related Eye Disease Study 2 (AREDS2), which was recently published in JAMA Ophthalmology , will be reviewed and discussed among leading vision care professionals during a live, complimentary webinar, ” More InSight: A Closer Look at the Brand new AREDS2 Data and What It Means For Patients ” on Tuesday, Oct. 18, 2022 , through 8: 00-9: 00 p. m. ET .

The hour-long webinar is specifically designed to help  eye care professionals understand the new results and come away with knowledge associated with how it can be integrated into practice to support Age-related Macular Degeneration (AMD) patients. The session, which will be moderated by Paul Karpecki, O. D., clinical director, Kentucky Eye Institute, will also spotlight clinical insights from Emily Chew , M. D., chair, AREDS2 Study, NEI, and feature expert commentary from panelists Jeffry Gerson , O. D., Grin Vision Care, Kansas City, Mo. , plus Rishi Singh , M. D., president, Cleveland Clinic Martin North and South Hospitals, Cleveland .

“With the AREDS2 10 Year Follow-on Study, we now have more than two decades of research demonstrating the impact that a specific nutrient formula can have on individuals with moderate to advanced AMD, ” said Dr . Chew. “The purpose of the ‘More InSight’ webinar is to discuss that impact – which further supports NEI’s current recommendation associated with a specific combination of six nutrients, including lutein, zeaxanthin and antioxidants, plus how doctors can implement these learnings in daily practice. ”

“Together along with Drs. Chew, Gerson, Karpecki and Singh, we look forward to providing attention care professionals with the particular opportunity to learn more about these latest research outcomes as well as obtain insightful takeaways that can enhance their AMD practices and support the millions associated with people impacted  by average to sophisticated AMD, inch said Joe Gordon, president, Global Consumer, Surgical and Vision Care, Bausch + Lomb.  

To register for the particular ‘More InSight’ webinar, visit www.reviewofophthalmology.com/more-insight-1018 .  

About ADVANCED MICRO DEVICES
Age-related Macular Degeneration (AMD) is a progressive eye condition that impacts central vision and is a leading cause of blindness in adults 50 years of age and older. Early-stage AMD often does not present any symptoms or changes in vision, as symptoms usually appear gradually over time. This progressive condition can impact one or both eyes, causing people to have difficulty with every day activities like driving, reading or recognizing the faces of loved ones. ^two  

About the AREDS, AREDS2 and 10-Year Follow-on AREDS2 Study Results
The AREDS and AREDS2 studies are landmark medical studies conducted over 20 years by the NEI. The particular AREDS study in 2001 demonstrated that will taking a specific combination of antioxidants and zinc could help reduce the risk of progression of ADVANCED MICRO DEVICES in those with moderate in order to advanced AMD. In 2012, the NEI completed the particular AREDS2 research, which tested several changes to the formulation, such as adding omega-3 fatty acids, substituting lutein plus zeaxanthin for beta-carotene, and/or reducing zinc. The present AREDS2 nutritional formula recommended by the NEI is the result of this study.

The NEI 10-Year Follow-on Study results evaluated the long-term results of participants who were involved inside the AREDS2 study. Consisting of 3, 883 people (6, 351 study eyes) with moderate to advanced ADVANCED MICRO DEVICES over the 10-year period, the follow-on study further validates the particular original findings of the AREDS2 formula with lutein and zeaxanthin, demonstrating an incremental reduction in danger of the particular progression in order to late-stage AMD. ¹  

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the particular moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye maintenance systems, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research plus development, manufacturing and commercial footprint with more than 12, 000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario along with corporate offices in Bridgewater, New Jersey . With regard to more information, visit  www.bausch.com   and connect with us on Twitter , LinkedIn , Facebook and Instagram .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally end up being identified by the use of the words “anticipates, inches “hopes, ” “expects, inch “intends, inches “plans, ” “should, inch “could, inches “would, ” “may, inch “believes, inches “estimates, ” “potential, inch “target, inches or “continue” and variations or similar expressions. These statements are usually based upon the current expectations and beliefs of management and are subject to certain risks plus uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the particular risks and uncertainties discussed in Bausch + Lomb’s filings with the U. S. Securities plus Exchange Commission and the Canadian Securities Administrators, which usually factors are usually incorporated herein by reference. They also include, but are not restricted to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the particular fear of that will pandemic plus its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which might have a material adverse impact on Bausch + Lomb, including but not limited to its project development timelines, launches and costs (which may increase). Readers are usually cautioned not to place undue reliance upon any associated with these forward-looking statements. These types of forward-looking claims speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any kind of these forward-looking statements to reflect events or even circumstances after the time of this particular news release or to reveal actual outcomes, unless required by law.

*Compared to sufferers taking the original AREDs formula

References  

1. Chew EY, Clemons TE, Agrón E, et al. Long-term Outcomes of Adding Lutein/Zeaxanthin plus ω-3 Fatty Acids towards the AREDS Supplements on Age-Related Macular Deterioration Progression:   AREDS2 Report 28.   JAMA Ophthalmology.   2022; 140(7): 692–698. doi: 10. 1001/jamaophthalmol. 2022. 1640National Eye Institute: Age-Related Macular Degeneration .  
2. Based on the AREDS and AREDS2 studies.  

AREDS plus AREDS2 are registered trademarks of the particular United States Department associated with Health and Human Services (HHS).  
Any other product/brand names are usually trademarks of the respective owners.  
© 2022 Bausch & Lomb Incorporated or even its affiliates.  
PV2. 0108. USA. 22

SOURCE Bausch + Lomb Company